Company: Pacific Biosciences
Based: Menlo Park, CA
Investors: Gen-Probe, unnamed investors
Scoop: A perennial contender in our list of the top VC deals each year, Pacific Biosciences once again comes out on top with a $109 million Series F haul. The company is preparing to commercialize its SMRT technology, which uses nanofabrication, biochemistry, molecular biology, surface chemistry and optics to enable real-time analysis of biomolecules. The funding included a $50 million strategic investment made by by Gen-Probe.
This will be the last year PacBio graces this list. The 2009 Fierce 15 company raised $200 million in its initial public offering in October 2010. The company sold 12.5 million shares for $16 each, pricing it in the middle of its targeted $15 to $17 range. All told, PacBio raised $370 million in venture funds before going public.